Astellas Pharma's Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
CompanyDrug

Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer

Sichuan Kelun-Biotech's Ketailai Receives NMPA Approval for Nasopharyngeal Carcinoma Treatment
CompanyDrug

Sichuan Kelun-Biotech’s Ketailai Receives NMPA Approval for Nasopharyngeal Carcinoma Treatment

Sino Biopharmaceutical's Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China
CompanyDeals

Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China

HutchMed's Orpathys Receives Priority Review for NSCLC Treatment in China
CompanyDrug

HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China

Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC
CompanyDeals

Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC

Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
CompanyDeals

Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing

Zhaoke Ophthalmology's TAB014 Achieves Positive Phase III Results for wAMD
CompanyDrug

Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD

HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
CompanyDeals

HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million

CompanyMedical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Alphamab Oncology's JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
CompanyDrug

Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer

Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
CompanyDrug

Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema

Johnson & Johnson's Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
CompanyDrug

Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment